Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Timothy Smallwood

Nurse Practitioner, Family Lexington, KY Nurse Practitioner

NPI 1437745163 CMS profile 11194470

177 Burt Rd, Lexington, KY 40503

Open in the dashboard

General payments

$26,638

618 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Smallwood of Lexington, KY is reported in the CMS Open Payments database as having received $26,638 across 618 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,021 195
2024 General $3,535 124
2023 General $1,742 79
2022 General $2,234 122
2021 General $2,106 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Smallwood
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Timothy Smallwood were reported at $17,021. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Timothy Smallwood Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,106 $124 $35–$379 $132
2022 $2,234 $141 $44–$430 $149
2023 $1,742 $154 $49–$476 $160
2024 $3,535 $165 $51–$504 $164
2025 $17,021 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Galderma Laboratories, L.P. $9,717 32 payments
  2. AbbVie, Inc. $2,880 132 payments
  3. Genzyme Corporation $2,554 47 payments
  4. E.R. Squibb & Sons, L.L.C. $1,699 32 payments
  5. Janssen Biotech, Inc. $1,602 72 payments
  6. Regeneron Healthcare Solutions, Inc. $1,401 35 payments
  7. Ortho Dermatologics, a division of Bausch Health US, LLC $998 4 payments
  8. Novartis Pharmaceuticals Corporation $939 51 payments
  9. UCB, Inc. $795 36 payments
  10. Lilly USA, LLC $641 39 payments
  11. Other $3,411 138 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $13,212 594 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,405 8 payments
  3. Consulting Fee $2,035 3 payments
  4. Education $978 12 payments
  5. Travel and Lodging $8 1 payment
Products named General payments · program years 2021–2025
  1. NEMLUVIO $9,599 26 payments
  2. DUPIXENT Immunology $3,057 65 payments
  3. TREMFYA $1,857 75 payments
  4. SKYRIZI Immunology $1,187 58 payments
  5. Cabtreo $998 4 payments
  6. SILIQ $950 2 payments
  7. DUPIXENT Inflammation And Immunology $947 22 payments
  8. VTAMA $637 18 payments
  9. SKYRIZI Immunology $636 22 payments
  10. TALTZ $635 38 payments
  11. Other $7,255 355 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,476

Median for Nurse Practitioner: 389

Drug cost

$1,711,751

Median for Nurse Practitioner: $21,885

Branded share of claims

14.9%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 26 $505,768
Dupixent Pen Dupilumab Brand 106 $388,881
Cosentyx Unoready Pen Secukinumab Brand 25 $249,408
Otezla Apremilast Brand 39 $185,896
Cosentyx Sensoready Pen Secukinumab Brand 12 $174,755
Humira(Cf) Pen Adalimumab Brand 12 $152,727
Tacrolimus Generic 51 $10,138
Calcipotriene Generic 25 $6,525
Clobetasol Propionate Generic 166 $6,266
Fluorouracil Generic 67 $6,145

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 47 billing codes

Paid by Medicare

$64,824

Of which drugs: $9,044

Medicare patients

284

Average age 71

Services billed

4,932

145 women, 139 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 41%
Diabetes 35%
Ischemic heart disease 34%
Chronic kidney disease 20%
COPD 19%
Depression 16%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $391
  • GENZYME CORPORATION $274
$665 106 —
SKYRIZI
  • AbbVie, Inc. $474
$474 26 —
TREMFYA
  • Janssen Biotech, Inc. $319
$319 — —
RINVOQ
  • AbbVie, Inc. $318
$318 — —
VTAMA
  • Dermavant Sciences, Inc. $260
$260 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

618 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record